Merck & Co., Inc. (NYSE:MRK) Shares Acquired by Regent Peak Wealth Advisors LLC


Share on StockTwits

Regent Peak Wealth Advisors LLC raised its position in shares of Merck & Co., Inc. (NYSE:MRK) by 15.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,996 shares of the company’s stock after acquiring an additional 4,048 shares during the quarter. Merck & Co., Inc. makes up about 0.8% of Regent Peak Wealth Advisors LLC’s holdings, making the stock its 27th largest holding. Regent Peak Wealth Advisors LLC’s holdings in Merck & Co., Inc. were worth $2,312,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Flagship Private Wealth LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $27,000. Financial Avengers Inc. acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $28,000. Joseph P. Lucia & Associates LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $29,000. Curi Capital acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $29,000. Finally, Veritas Investment Partners UK Ltd. acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $30,000. 72.86% of the stock is owned by hedge funds and other institutional investors.

NYSE:MRK traded down $0.20 during midday trading on Tuesday, reaching $75.78. The company had a trading volume of 445,356 shares, compared to its average volume of 11,885,203. The firm has a market capitalization of $191.75 billion, a price-to-earnings ratio of 16.81, a PEG ratio of 1.89 and a beta of 0.43. The stock’s fifty day simple moving average is $76.83 and its 200-day simple moving average is $78.38. Merck & Co., Inc. has a 12-month low of $71.71 and a 12-month high of $87.80. The company has a current ratio of 1.30, a quick ratio of 1.00 and a debt-to-equity ratio of 0.90.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Thursday, April 29th. The company reported $1.40 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.63 by ($0.23). Merck & Co., Inc. had a net margin of 24.33% and a return on equity of 53.83%. The company had revenue of $12.08 billion during the quarter, compared to analysts’ expectations of $12.71 billion. During the same quarter last year, the business posted $1.50 earnings per share. The company’s revenue for the quarter was up .2% on a year-over-year basis. As a group, sell-side analysts expect that Merck & Co., Inc. will post 5.9 EPS for the current year.

Several research analysts recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Merck & Co., Inc. in a research report on Friday, February 5th. SVB Leerink lowered their price objective on Merck & Co., Inc. from $103.00 to $102.00 and set an “outperform” rating for the company in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Merck & Co., Inc. has a consensus rating of “Buy” and a consensus target price of $97.22.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products.

Recommended Story: Index Funds

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.